Patents by Inventor Kent Bondensgaard

Kent Bondensgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating pruritic disease with IL-31 monoclonal antibodies
    Patent number: 11542327
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: January 3, 2023
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • METHODS OF TREATING PRURITIC DISEASE WITH IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20200262913
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: March 30, 2020
    Publication date: August 20, 2020
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies
    Patent number: 10640559
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 5, 2020
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • NUCLEIC ACID MOLECULES ENCODING HUMANIZED IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20180305448
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: April 26, 2018
    Publication date: October 25, 2018
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Method of treating pruritus with IL-31 monoclonal antibody formulations
    Patent number: 9982044
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • METHOD OF TREATING PRURITUS WITH IL-31 MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20170313768
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 2, 2017
    Inventors: Kent Bondensgaard, Roland Beckmann
  • IL-31 monoclonal antibody formulations
    Patent number: 9738715
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 22, 2017
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • IL-31 MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20160311898
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 27, 2016
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Method of treating pruritus with IL-31 monoclonal antibodies
    Patent number: 9416184
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 16, 2016
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • METHOD OF TREATING PRURITUS WITH IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20150183868
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Polynucleotides encoding IL-31 monoclonal antibodies
    Patent number: 9005921
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 14, 2015
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20140186891
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicants: Merck Serono S/A, ZymoGenetics, Inc.
    Inventors: Kent BONDENSGAARD, Roland Beckmann
  • Nucleic acid molecules encoding humanized antibody molecules specific for IL-31
    Patent number: 8685669
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 1, 2014
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31
    Publication number: 20130295611
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: June 3, 2013
    Publication date: November 7, 2013
    Inventors: Kent Bondensgaard, Roland Beckmann
  • IL-21 variants
    Patent number: 8475784
    Abstract: IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: July 2, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • Humanized antibody molecules specific for IL-31
    Patent number: 8470979
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: June 25, 2013
    Assignees: ZymoGenetics, Inc., Merck Serono S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Interleukin-21 variants with altered binding to the IL-21 receptor
    Patent number: 8211420
    Abstract: The invention is concerned with IL-21 polypeptide variants having an altered binding to the common gamma chain (c) of the IL-21 receptor and the use thereof in therapy.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: July 3, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Kent Bondensgaard, Lishan Kang, Siv Annegrethe Hjorth, Dennis Madsen
  • INTERLEUKIN-21 VARIANTS HAVING ANTAGONISTIC BINDING TO THE IL-21 RECEPTOR
    Publication number: 20120107267
    Abstract: The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.
    Type: Application
    Filed: March 10, 2010
    Publication date: May 3, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Lishan Kang, Kent Bondensgaard, Siv Annegrethe Hjorth
  • IL-21 VARIANTS
    Publication number: 20120082996
    Abstract: IL-21 variants nucleic acid sequences are provided that encode a peptide having deletions and zero to ten conservative amino acid substitutions in the region of amino acid residues 65-96 of SEQ ID. NO:2.
    Type: Application
    Filed: September 19, 2011
    Publication date: April 5, 2012
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen
  • IL-21 variants
    Patent number: 8034326
    Abstract: IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: October 11, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Siv Annegrethe Hjorth, Kent Bondensgaard, Dennis Madsen